Literature DB >> 10811075

Outcomes and complications associated with perfluoro-n-octane and perfluoroperhydrophenanthrene in complex retinal detachment repair.

I U Scott1, T G Murray, H W Flynn, W E Smiddy, W J Feuer, J C Schiffman.   

Abstract

OBJECTIVE: To compare rates of perfluorocarbon liquid (PFCL) intraocular retention, anatomic and visual acuity outcomes, and complications associated with intraoperative perfluoro-n-octane (Perfluoron) versus perfluoroperhydrophenanthrene (Vitreon) in retinal detachment repair.
DESIGN: Retrospective noncomparative consecutive case series. PARTICIPANTS AND METHODS: Records of consecutive patients who underwent retinal detachment repair with intraoperative Perfluoron (n = 78) or Vitreon (n = 84) at the Bascom Palmer Eye Institute between November 1, 1991, and October 31, 1994, were retrospectively reviewed. MAIN OUTCOME MEASURES: Comparison of PFCL intraocular retention rates, retinal reattachment rates, visual acuity outcomes, and postoperative complication rates between the Perfluoron and Vitreon groups at postoperative day 1, week 1, month 1, month 3, and month 6. To assess the study's generalizability, the Perfluoron data obtained in the current study were compared with results of the Perfluoron Multicenter Clinical Study.
RESULTS: Retained Perfluoron was noted less frequently (P < 0.03) than retained Vitreon at each postoperative visit assessed. At 6 months postoperatively, the cumulative rate of retained PFCL (noted at any of the study postoperative visits) was 7.8% of patients in the Perfluoron group and 38.3% in the Vitreon group (P < 0.001). No significant difference was found between the groups in retinal reattachment rates; at 6 months postoperatively, the retina was attached in 45 of 61 (74%) patients in the Perfluoron group and 36 of 57 (63%) patients in the Vitreon group (P = 0.2). There was a trend (P = 0.055) toward better 6-month visual acuity in the Perfluoron group compared with the Vitreon group. The incidence of corneal abnormality at any study visit was 46.7% in the Perfluoron group and 77.4% in the Vitreon group (P < 0.001). At 6 months postoperatively, the cumulative rate of elevated intraocular pressure (>25 mmHg) was 13 +/- 4% and 37 +/- 5%, respectively (P = 0.004). No significant difference was found between the groups in rates of postoperative hypotony. Results of this study are comparable with those observed in the Perfluoron Multicenter Clinical Study.
CONCLUSIONS: In this study, Perfluoron was retained intraocularly less frequently than Vitreon. Although no significant difference was found between groups in retinal reattachment rates, Perfluoron is associated with slightly better 6-month visual acuity and lower rates of corneal abnormality and elevated intraocular pressure compared with Vitreon.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811075     DOI: 10.1016/s0161-6420(00)00076-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

1.  Intracranial hyperdense subarachnoid perfluorocarbon droplets after attempted retinal detachment treatment.

Authors:  David R Malin; Joseph M Aulino; Franco M Recchia
Journal:  Emerg Radiol       Date:  2007-02-21

2.  Double Retinal Tamponade for Treatment of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy and Inferior Breaks.

Authors:  Mohamed Farouk Abdelkader; Shaaban Abd-Elhamid Mehany Elwan; Ahmed Shawkat Abdelhalim
Journal:  J Ophthalmol       Date:  2020-10-07       Impact factor: 1.909

3.  CT characteristics of intraocular perfluoro-N-octane.

Authors:  John B Christoforidis; Paul A Caruso; Hugh D Curtin; Tito Fiore; Donald J D'Amico
Journal:  AJNR Am J Neuroradiol       Date:  2003-10       Impact factor: 3.825

4.  Release and extraction of retained subfoveal perfluorocarbon liquid facilitated by subretinal BSS, vibration, and gravity: a case report.

Authors:  Kosuke Takahashi; Shuhei Kimura; Mio Morizane Hosokawa; Yusuke Shiode; Shinichiro Doi; Ryo Matoba; Yuki Kanzaki; Yoshihiro Yonekawa; Yuki Morizane
Journal:  BMC Ophthalmol       Date:  2020-10-23       Impact factor: 2.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.